文献速递甲状腺疾病

多模式治疗对未分化甲状腺癌生存的改善

Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

该回顾性分析纳入2003至2015年在梅奥诊所诊治的48例新诊断未分化甲状腺癌患者,其中30例接受初始强化多模式治疗(MMT),18例接受姑息意向治疗(PI)。后期队列中位总生存为9个月(95%CI 4–22个月),1年生存率为42%(95%CI 28%–56%);早期队列分别为3个月和10%。在IVB期患者中,MMT组中位总生存为22.4个月,PI组为4个月(HR 0.12;95%CI 0.03–0.44;P=0.0001),1年生存率分别为68%和0%;在IVC期患者中,两种治疗的总生存无差异。结论认为,在IVA/B期患者中,MMT似乎与更长的生存相关。

要点

  • 后期队列中位总生存9个月(95%CI 4–22个月),1年生存率42%(95%CI 28%–56%)。
  • 在后期队列中,MMT组中位总生存为21个月,PI组为3.9个月(HR 0.32;P=0.0006)。
  • IVB期患者中,MMT组中位总生存22.4个月,PI组4个月(HR 0.12;95%CI 0.03–0.44;P=0.0001)。

核心结论

  • 在IVA/B期未分化甲状腺癌患者中,初始强化多模式治疗似乎与更长的生存相关。

研究设计与样本

  • 回顾性分析梅奥诊所2003年至2015年诊治的48例新诊断未分化甲状腺癌患者,其中30例接受MMT,18例接受PI。
  • 按美国癌症联合委员会分期比较结局,并与1949年至1999年患者队列数据进行比较。

主要发现

  • 后期队列中位总生存为9个月(95%CI 4–22个月),1年生存率为42%(95%CI 28%–56%);早期队列分别为3个月和10%。
  • 后期队列中,MMT组中位总生存为21个月,PI组为3.9个月(HR 0.32;P=0.0006)。
  • IVB期患者中,MMT组中位总生存为22.4个月,PI组为4个月(HR 0.12;95%CI 0.03–0.44;P=0.0001),1年生存率分别为68%和0%。
  • IVC期患者中,两种治疗的总生存无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Historical outcomes in anaplastic thyroid cancer (ATC) have been dismal. OBJECTIVE: To determine whether an initial intensive multimodal therapy (MMT) is associated with improved ATC survival. DESIGN: MMT was offered to all patients with newly diagnosed ATC treated at the Mayo Clinic from 2003 through 2015; MMT vs care with palliative intent (PI) was individualized considering clinical status and patient preferences. Outcomes were retrospectively analyzed by American Joint Committee on Cancer stage and treatments compared with patient cohort data from 1949 through 1999. PATIENTS: Forty-eight patients (60% male; median age, 62 years); 18 treated with PI, 30 with MMT. MAIN OUTCOME MEASURE: Overall survival (OS) and progression-free survival determined by Kaplan-Meier method. RESULTS: Median OS and 1-year survival for the later cohort were 9 months [95% confidence interval (CI), 4 to 22 months] and 42% (95% CI, 28% to 56%) vs 3 months and 10% for the earlier cohort. Median OS was 21 months compared with 3.9 months in the pooled MMT vs PI groups for the later cohort [hazard ratio (HR), 0.32; P = 0.0006]. Among only patients in the later cohort who had stage IVB disease, median OS was 22.4 vs 4 months (HR, 0.12; 95% CI, 0.03 to 0.44; P = 0.0001), with 68% vs 0% alive at 1 year (MMT vs PI). Among patients with stage IVC cancer, OS did not differ by therapy. CONCLUSION: MMT appears to convey longer survival in ATC among patients with stage IVA/B disease.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Prasongsook N, Kumar A, Chintakuntlawar AV, et al. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. J Clin Endocrinol Metab. 2017. PMID: 29029287. doi:10.1210/jc.2017-01180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。